Kevin Joseph Harrington

55PUBLICATIONS
493CO-AUTHORS
Molecular targetsPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)ChemotherapyTumour immunology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (55)

|Sep 15, 2026
Amivantamab plus pembrolizumab in previously untreated recurrent/metastatic head and neck squamous cell cancer: Results from the phase 1b/2 OrigAMI-4 study.

|Aug 19, 2026
Danvatirsen plus pembrolizumab versus pembrolizumab for recurrent and/or metastatic head and neck squamous cell carcinoma (PEMDA-HN): a randomized, phase 2 trial.

|Jul 30, 2026
"SMAC"-down for the apoptosis-restoring drug, Xevinapant: What does its story reveal?

|Jun 26, 2026
Tumour Mutational Burden and Its Relationship with Clinical Outcomes in Locally Advanced and Recurrent/Metastatic Adenoid Cystic Carcinoma with and Without NOTCH Pathway Activation.

|Jun 05, 2026
Engagement of the TCR against an oncolytic virus generates a population of effector CAR T cells with potent antitumor activity.

|May 31, 2026
Amivantamab in Recurrent/Metastatic Head and Neck Squamous Cell Cancer After Checkpoint Inhibitor and Chemotherapy: Pivotal Results From the Phase Ib/II OrigAMI-4 Study.

Pageof 10

Frequent Collaborators

15 joint publications

Alan Melcher

11 joint publications

Emmanuel Patin

9 joint publications

Pablo Nenclares

8 joint publications

Robert I Haddad